Early Impact of Bevacizumab on the 99mTc-HYNIC-PSMA-11 Uptake in a Case of Recurrent Glioblastoma Multiforme-Reference-Cited by-同舟云学术

Early Impact of Bevacizumab on the 99mTc-HYNIC-PSMA-11 Uptake in a Case of Recurrent Glioblastoma Multiforme

Published:2024-10 Issue:10 Volume:49 Page:e528-e529
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Ghaedian Tahereh¹,Alipour Abdolmajid¹,Rakhsha Abbas²,Nasrollahi Hamid³,Saffarian Arash²

Affiliation:

1. Nuclear Medicine Department, Namazi Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2. Department of Neurosurgery, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

3. Department of Radiooncology, Namazi Teaching Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Abstract Glioblastoma multiforme (GBM) is a highly vascularized tumor with reported high prostate-specific membrane antigen (PSMA) expression. On the other hand, bevacizumab as an antiangiogenesis drug is increasingly used in the treatment of GBM recurrence. We present a case of GBM recurrence with significant reduction of 99mTc-HYNIC-PSMA-11 uptake in her tumor 1 week after administration of 2 doses of bevacizumab with 2 weeks’ interval. This case emphasizes the main mechanism of PSMA uptake in GBM secondary to angiogenesis and also implies a potential interaction of bevacizumab with PSMA uptake that should be especially considered during diagnostic and therapeutic application of PSMA radiotracers in GBM.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference9 articles.

1. Bevacizumab for the treatment of glioblastoma;Clin Med Insights Oncol,2013

2. Primary malignant brain tumor trends in southern Iran, 2001–2017: an alarming increase in glioblastoma;J Surg Res,2022

3. Angiogenesis in brain tumours;Nat Rev Neurosci,2007

4. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment;Brain Tumor Pathol,2024

5. PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging;Front Oncol,2021